✦ LIBER ✦

Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trial

✍ Scribed by Heikki Joensuu; Pirkko-Liisa Kellokumpu-Lehtinen; Riikka Huovinen; Arja Jukkola-Vuorinen; Minna Tanner; Raija Asola; Riitta Kokko; Johan Ahlgren; Päivi Auvinen; Akseli Hemminki; Outi Paija; Leena Helle; Lauri Nuortio; Kenneth Villman; Greger Nilsson; Sirpa-Liisa Lahtela; Kaisa Lehtiö; Marjo Pajunen; Paula Poikonen; Paul Nyandoto; Vesa Kataja; Petri Bono; Mika Leinonen; Henrik Lindman

Book ID: 117785176
Publisher: The Lancet
Year: 2009
Tongue: English
Weight: 178 KB
Volume: 10
Category: Article
ISSN: 1470-2045
DOI: 10.1016/s1470-2045(09)70307-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Sequential docetaxel as adjuvant chemoth

Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial

✍ Paul Ellis; Peter Barrett-Lee; Lindsay Johnson; David Cameron; Andrew Wardley; S 📂 Article 📅 2009 🏛 The Lancet 🌐 English ⚖ 290 KB

Sequential docetaxel as adjuvant chemoth

Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial

✍ Glück, S. 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 106 KB

Adjuvant docetaxel and cyclophosphamide

Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study

✍ Jones, Stephen E; Collea, Rufus; Paul, Devchand; Sedlacek, Scot; Favret, Anne M; 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 210 KB

Adjuvant chemotherapy and timing of tamo

Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial

✍ Kathy S Albain; William E Barlow; Peter M Ravdin; William B Farrar; Gary V Burto 📂 Article 📅 2009 🏛 The Lancet 🌐 English ⚖ 145 KB

Maintenance capecitabine and bevacizumab

Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial

✍ Gligorov, Joseph; Doval, Dinesh; Bines, José; Alba, Emilio; Cortes, Paulo; Pierg 📂 Article 📅 2014 🏛 The Lancet 🌐 English ⚖ 364 KB

Effects of the addition of gemcitabine,

Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2×2 factorial randomised phase 3 trial

✍ Earl, Helena M; Vallier, Anne-Laure; Hiller, Louise; Fenwick, Nicola; Young, Jen 📂 Article 📅 2014 🏛 The Lancet 🌐 English ⚖ 349 KB